Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Total Liabilities for 6 consecutive years, with $105.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 18.81% to $105.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105.7 million through Dec 2025, down 18.81% year-over-year, with the annual reading at $105.7 million for FY2025, 18.81% down from the prior year.
  • Total Liabilities for Q4 2025 was $105.7 million at TScan Therapeutics, down from $118.2 million in the prior quarter.
  • The five-year high for Total Liabilities was $130.1 million in Q4 2024, with the low at $20.8 million in Q2 2022.
  • Average Total Liabilities over 5 years is $87.5 million, with a median of $111.8 million recorded in 2024.
  • The sharpest move saw Total Liabilities plummeted 54.91% in 2022, then skyrocketed 508.37% in 2023.
  • Over 5 years, Total Liabilities stood at $27.3 million in 2021, then soared by 264.66% to $99.7 million in 2022, then increased by 21.7% to $121.3 million in 2023, then rose by 7.31% to $130.1 million in 2024, then dropped by 18.81% to $105.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $105.7 million, $118.2 million, and $121.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.